Coronavirus Update: Two UK-Backed Vaccines Progress, Cross-Industry Database Launched, Roche's Schwan On COVID-19 Impact
Adenovirus and mRNA Candidates Move Into Phase I
Plus: Korea's Dong Wha readies potent antiviral for trials, and Pharming's candidate shows promise in compassionate use.
You may also be interested in...
Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesivir Filing
Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic.
Experience from previous viral outbreaks has allowed the UK agency to move quickly; long-term focus is on hybrid inspection approach.
Oxford University vaccines expert Sarah Gilbert says the first UK vaccine candidate to prevent the SARS-CoV-2 coronavirus will begin clinical testing in healthy volunteers next week and that “prospects are very good” an effective COVID19 jab could be available by September.